What is Heron Therapeutics Debt-to-Equity?
Heron Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.1 Mil. Heron Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $176.6 Mil. Heron Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-34.0 Mil.
Heron Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -5.29.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Heron Therapeutics's Debt-to-Equity or its related term are showing as below:
HRTX'
s Debt-to-Equity Range Over the Past 10 Years
Min: -5.29 Med: 0.04 Max: 11.6
Current: -5.29
During the past 13 years, the highest Debt-to-Equity Ratio of Heron Therapeutics was 11.60. The lowest was -5.29. And the median was 0.04.
Heron Therapeutics Debt-to-Equity Historical Data
The historical data trend for Heron Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heron Therapeutics Debt-to-Equity Chart
|
Heron Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
0.05 |
0.10 |
2.06 |
11.60 |
-5.29 |
|
Heron Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
11.60 |
-13.73 |
-3.97 |
-6.48 |
-5.29 |
Competitive Comparison of Heron Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Heron Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heron Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heron Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Heron Therapeutics's Debt-to-Equity falls into.
Heron Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Heron Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Heron Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Heron Therapeutics (Heron Therapeutics) Business Description
Traded in Other Exchanges
Address
4242 Campus Point Court, Suite 200, San Diego, CA, USA, 92121
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.
Executives
| William P Forbes |
officer: EVP, Chief Development Officer |
C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615 |
| Adam Morgan |
other: See Footnote 2 |
1055B POWERS PLACE, ALPHARETTA GA 30009 |
| Ira Duarte |
officer: EVP, Chief Financial Officer |
1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
| Craig A Collard |
director |
C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518 |
| Kevin Kotler |
director |
C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
| Velan Capital Master Fund Lp |
other: See Footnote 2 |
1055B POWERS PLACE, ALPHARETTA GA 30009 |
| Velan Capital Management Llc |
other: See Footnote 2 |
1055B POWERS PLACE, ALPHARETTA GA 30009 |
| Velan Capital Holdings Llc |
other: See Footnote 2 |
1055B POWERS PLACE, ALPHARETTA GA 30009 |
| Velan Capital Investment Management Lp |
other: See Footnote 2 |
1055B POWERS PLACE, ALPHARETTA GA 30009 |
| David Efraim Rosen |
other: See Footnote 1 |
155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017 |
| Rubric Capital Management Lp |
other: See Footnote 1 |
155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017 |
| Balaji Venkataraman |
other: See Footnote 2 |
FIRST HORIZON PHARMACEUTICAL CORP, 660 HEMBREE PKWY STE 106, ROSWELL GA 30076 |
| Kimberly Manhard |
director |
C/O HERON THERAPEUTICS, INC, 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO CA 92121 |
| Craig A Johnson |
director |
C/O PURE BIOSCIENCE, 1725 GILLESPIE WAY, EL CAJON CA 92020 |
| Waage Christian |
director |
RECEPTOS, INC., 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121 |
Heron Therapeutics (Heron Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HRTX has been successfully added to your